Collateral damage from oral ciprofloxacin versus nitrofurantoin in outpatients with urinary tract infections: a culture-free analysis of gut microbiota/Experiment 1
From BugSigDB
Reviewed Marked as Reviewed by Claregrieve1 on 2022/10/31
Subjects
- Location of subjects
- Switzerland
- Host species Species from which microbiome was sampled. Contact us to have more species added.
- Homo sapiens
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Antimicrobial agent antibiotic,antibiotics,Antibiotika,Antibiotikum,antibiotique,antimicrobial,antimicrobial agents,microbicide,microbicides,Antimicrobial agent,antimicrobial agent
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- baseline of the ciprofloxacin treated
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- ciprofloxacin treated
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- UTI patients treated with ciprofloxacin 500mg twice daily
- Group 0 sample size Number of subjects in the control (unexposed) group
- 10
- Group 1 sample size Number of subjects in the case (exposed) group
- 10
- Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
- 2 months
Lab analysis
- Sequencing type
- 16S
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- V3-V4
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- Roche454
Statistical Analysis
- Statistical test
- Mann-Whitney (Wilcoxon)
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
- MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
- No
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- unchanged
- Chao1 Abundance-based estimator of species richness
- unchanged
- Simpson Estimator of species richness and species evenness: more weight on species evenness
- unchanged
Signature 1
Reviewed Marked as Reviewed by Claregrieve1 on 2022/10/31
Source: Figure 3
Description: Differential microbial abundance between baseline (timepoint 1) and timepoint 2 in ciprofloxacin treated patients
Abundance in Group 1: decreased abundance in ciprofloxacin treated
| NCBI | Quality Control | Links |
|---|---|---|
| Bifidobacteriaceae | ||
| Faecalibacterium | ||
| Oscillospira | ||
| Oscillospiraceae | ||
| Ruminococcus |
Revision editor(s): Mmarin, Claregrieve1
Signature 2
Reviewed Marked as Reviewed by Claregrieve1 on 2022/10/31
Source: Figure 3
Description: Differential microbial abundance between baseline (timepoint 1) and timepoint 2 in ciprofloxacin treated patients
Abundance in Group 1: increased abundance in ciprofloxacin treated
| NCBI | Quality Control | Links |
|---|---|---|
| Bacteroidaceae | ||
| Blautia | ||
| Clostridium | ||
| Eubacterium | ||
| Lachnospiraceae | ||
| Roseburia |
Revision editor(s): Mmarin, Claregrieve1
